questionsmedicales.fr
Phénomènes physiologiques de l'appareil locomoteur et du système nerveux
Phénomènes physiologiques du système nerveux
Inhibition nerveuse
Inhibition nerveuse : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Diagnostic Neurologique
Électrophysiologie
Électromyographie
Potentiels Évoqués
Faiblesse Musculaire
Réflexes
Imagerie par Résonance Magnétique
Anomalies Nerveuses
Mesure Électrique
Neurones
Symptômes
5
Spasmes Musculaires
Activité Nerveuse
Troubles Cognitifs
Mémoire
Motricité
Faiblesse Musculaire
Troubles Sensoriels
Picotements
Prévention
5
Exercice Physique
Circulation Nerveuse
Alimentation Équilibrée
Santé Nerveuse
Traitements
5
Analgésiques
Anti-inflammatoires
Réhabilitation
Coordination
Chirurgie Nerveuse
Compression Nerveuse
Acupuncture
Thérapies Alternatives
Complications
5
Douleurs Chroniques
Mobilité
Handicaps Fonctionnels
Inhibition Nerveuse
Dépression
Douleur Chronique
Qualité de Vie
Activités Quotidiennes
Facteurs de risque
5
Surpoids
Pression Nerveuse
Antécédents Familiaux
Troubles Nerveux
Tabagisme
Circulation Sanguine
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibition nerveuse : Questions médicales les plus fréquentes",
"headline": "Inhibition nerveuse : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibition nerveuse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-04",
"dateModified": "2025-03-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibition nerveuse"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phénomènes physiologiques du système nerveux",
"url": "https://questionsmedicales.fr/mesh/D009424",
"about": {
"@type": "MedicalCondition",
"name": "Phénomènes physiologiques du système nerveux",
"code": {
"@type": "MedicalCode",
"code": "D009424",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G11.561"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibition nerveuse",
"alternateName": "Neural Inhibition",
"code": {
"@type": "MedicalCode",
"code": "D009433",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Chiang-Shan R Li",
"url": "https://questionsmedicales.fr/author/Chiang-Shan%20R%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; Department of Neuroscience, Yale University School of Medicine, New Haven, CT, USA; Interdepartmental Neuroscience Program, Yale University School of Medicine, New Haven, CT, USA."
}
},
{
"@type": "Person",
"name": "Thang M Le",
"url": "https://questionsmedicales.fr/author/Thang%20M%20Le",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. Electronic address: thang.le@yale.edu."
}
},
{
"@type": "Person",
"name": "Barry R Komisaruk",
"url": "https://questionsmedicales.fr/author/Barry%20R%20Komisaruk",
"affiliation": {
"@type": "Organization",
"name": "Department Psychology, Rutgers University, Newark, NJ, USA. Electronic address: brk@psychology.rutgers.edu."
}
},
{
"@type": "Person",
"name": "Maria Cruz Rodriguez Del Cerro",
"url": "https://questionsmedicales.fr/author/Maria%20Cruz%20Rodriguez%20Del%20Cerro",
"affiliation": {
"@type": "Organization",
"name": "Department Psychobiology, Universidad Nacional de Educación a Distancia, Madrid, Spain."
}
},
{
"@type": "Person",
"name": "Sheng Zhang",
"url": "https://questionsmedicales.fr/author/Sheng%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Comparison of the Effect of Propranolol Combination with Cinnarizine and Propranolol in the Prevention of Acute Migraine Attacks.",
"datePublished": "2022-11-30",
"url": "https://questionsmedicales.fr/article/37114310",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.14715/cmb/2022.68.11.7"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Effect of Bevacizumab and Propranolol on Nasal Polyposis.",
"datePublished": "2022-10-12",
"url": "https://questionsmedicales.fr/article/36304979",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/6174664"
}
},
{
"@type": "ScholarlyArticle",
"name": "Monitoring oral propranolol for infantile hemangiomata.",
"datePublished": "2022-10-11",
"url": "https://questionsmedicales.fr/article/36177767",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/dth.15870"
}
},
{
"@type": "ScholarlyArticle",
"name": "Propranolol and infantile hemangiomas: Outcome from a tricentric study.",
"datePublished": "2022-11-23",
"url": "https://questionsmedicales.fr/article/36513008",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.bjps.2022.11.016"
}
},
{
"@type": "ScholarlyArticle",
"name": "Can Propranolol Affect Platelet Indices in Infantile Hemangioma?",
"datePublished": "2023-05-15",
"url": "https://questionsmedicales.fr/article/37278557",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MPH.0000000000002683"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes physiologiques de l'appareil locomoteur et du système nerveux",
"item": "https://questionsmedicales.fr/mesh/D055687"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phénomènes physiologiques du système nerveux",
"item": "https://questionsmedicales.fr/mesh/D009424"
},
{
"@type": "ListItem",
"position": 4,
"name": "Inhibition nerveuse",
"item": "https://questionsmedicales.fr/mesh/D009433"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibition nerveuse - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibition nerveuse",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibition nerveuse",
"description": "Comment diagnostiquer l'inhibition nerveuse ?\nQuels tests sont utilisés pour l'inhibition nerveuse ?\nQuels signes cliniques indiquent une inhibition nerveuse ?\nL'imagerie est-elle utile pour l'inhibition nerveuse ?\nPeut-on mesurer l'inhibition nerveuse ?",
"url": "https://questionsmedicales.fr/mesh/D009433?mesh_terms=Propranolol#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibition nerveuse",
"description": "Quels sont les symptômes de l'inhibition nerveuse ?\nL'inhibition nerveuse cause-t-elle des spasmes musculaires ?\nY a-t-il des symptômes cognitifs associés ?\nComment l'inhibition nerveuse affecte-t-elle la motricité ?\nL'inhibition nerveuse peut-elle causer des troubles sensoriels ?",
"url": "https://questionsmedicales.fr/mesh/D009433?mesh_terms=Propranolol#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibition nerveuse",
"description": "Comment prévenir l'inhibition nerveuse ?\nL'exercice régulier aide-t-il à prévenir l'inhibition nerveuse ?\nLes pauses au travail sont-elles importantes ?\nUne alimentation équilibrée peut-elle aider ?\nLe stress influence-t-il l'inhibition nerveuse ?",
"url": "https://questionsmedicales.fr/mesh/D009433?mesh_terms=Propranolol#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibition nerveuse",
"description": "Quels traitements existent pour l'inhibition nerveuse ?\nLes médicaments peuvent-ils aider l'inhibition nerveuse ?\nLa physiothérapie est-elle efficace ?\nQuand la chirurgie est-elle envisagée ?\nY a-t-il des thérapies alternatives pour l'inhibition nerveuse ?",
"url": "https://questionsmedicales.fr/mesh/D009433?mesh_terms=Propranolol#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibition nerveuse",
"description": "Quelles complications peuvent survenir ?\nL'inhibition nerveuse peut-elle entraîner des handicaps ?\nY a-t-il des risques de dépression associés ?\nDes troubles de la coordination peuvent-ils survenir ?\nL'inhibition nerveuse peut-elle affecter la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D009433?mesh_terms=Propranolol#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibition nerveuse",
"description": "Quels sont les facteurs de risque de l'inhibition nerveuse ?\nLe diabète est-il un facteur de risque ?\nLe surpoids influence-t-il l'inhibition nerveuse ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe tabagisme est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D009433?mesh_terms=Propranolol#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'inhibition nerveuse ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des examens neurologiques et des tests électrophysiologiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour l'inhibition nerveuse ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'EMG et les potentiels évoqués pour évaluer la conduction nerveuse."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une inhibition nerveuse ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme la faiblesse musculaire et des réflexes diminués peuvent indiquer une inhibition."
}
},
{
"@type": "Question",
"name": "L'imagerie est-elle utile pour l'inhibition nerveuse ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IRM peut aider à visualiser des anomalies structurelles affectant les nerfs."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer l'inhibition nerveuse ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests spécifiques mesurent l'activité électrique des neurones inhibés."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de l'inhibition nerveuse ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur, engourdissement, et perte de coordination."
}
},
{
"@type": "Question",
"name": "L'inhibition nerveuse cause-t-elle des spasmes musculaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des spasmes musculaires en raison d'une activité nerveuse altérée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cognitifs associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de la concentration et de la mémoire peuvent survenir avec l'inhibition nerveuse."
}
},
{
"@type": "Question",
"name": "Comment l'inhibition nerveuse affecte-t-elle la motricité ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut provoquer une faiblesse musculaire et des difficultés de mouvement."
}
},
{
"@type": "Question",
"name": "L'inhibition nerveuse peut-elle causer des troubles sensoriels ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des sensations anormales comme des picotements peuvent se manifester."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'inhibition nerveuse ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir une bonne posture et éviter les mouvements répétitifs peut aider à prévenir."
}
},
{
"@type": "Question",
"name": "L'exercice régulier aide-t-il à prévenir l'inhibition nerveuse ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice renforce les muscles et améliore la circulation nerveuse."
}
},
{
"@type": "Question",
"name": "Les pauses au travail sont-elles importantes ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, faire des pauses régulières réduit le risque de stress nerveux et de blessures."
}
},
{
"@type": "Question",
"name": "Une alimentation équilibrée peut-elle aider ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en nutriments soutient la santé nerveuse."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il l'inhibition nerveuse ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut exacerber les symptômes d'inhibition nerveuse."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour l'inhibition nerveuse ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la physiothérapie, les médicaments et parfois la chirurgie."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider l'inhibition nerveuse ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des analgésiques et des anti-inflammatoires peuvent soulager les symptômes."
}
},
{
"@type": "Question",
"name": "La physiothérapie est-elle efficace ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle aide à renforcer les muscles et améliorer la coordination."
}
},
{
"@type": "Question",
"name": "Quand la chirurgie est-elle envisagée ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est envisagée si les traitements conservateurs échouent ou en cas de compression nerveuse."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies alternatives pour l'inhibition nerveuse ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies comme l'acupuncture peuvent être bénéfiques pour certains patients."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des douleurs chroniques et des troubles de la mobilité."
}
},
{
"@type": "Question",
"name": "L'inhibition nerveuse peut-elle entraîner des handicaps ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des handicaps fonctionnels peuvent résulter d'une inhibition nerveuse sévère."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de dépression associés ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la douleur chronique liée à l'inhibition nerveuse peut contribuer à la dépression."
}
},
{
"@type": "Question",
"name": "Des troubles de la coordination peuvent-ils survenir ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'inhibition nerveuse peut affecter la coordination et l'équilibre."
}
},
{
"@type": "Question",
"name": "L'inhibition nerveuse peut-elle affecter la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut réduire la qualité de vie en limitant les activités quotidiennes."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de l'inhibition nerveuse ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, les blessures, et certaines maladies chroniques."
}
},
{
"@type": "Question",
"name": "Le diabète est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut endommager les nerfs et augmenter le risque d'inhibition nerveuse."
}
},
{
"@type": "Question",
"name": "Le surpoids influence-t-il l'inhibition nerveuse ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le surpoids peut exercer une pression sur les nerfs, augmentant le risque."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de troubles nerveux peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut nuire à la circulation sanguine et affecter les nerfs."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 29/03/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; Department of Neuroscience, Yale University School of Medicine, New Haven, CT, USA; Interdepartmental Neuroscience Program, Yale University School of Medicine, New Haven, CT, USA.
Publications dans "Inhibition nerveuse" :
3 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. Electronic address: thang.le@yale.edu.
Publications dans "Inhibition nerveuse" :
2 publications dans cette catégorie
Affiliations :
Department Psychology, Rutgers University, Newark, NJ, USA. Electronic address: brk@psychology.rutgers.edu.
Publications dans "Inhibition nerveuse" :
2 publications dans cette catégorie
Affiliations :
Department Psychobiology, Universidad Nacional de Educación a Distancia, Madrid, Spain.
Publications dans "Inhibition nerveuse" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Publications dans "Inhibition nerveuse" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Publications dans "Inhibition nerveuse" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Publications dans "Inhibition nerveuse" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Ave, Cleveland, Ohio, 44106.
Department of Pediatrics, Case Western Reserve University, 2109 Adelbert Rd, Cleveland, Ohio, 44106.
Publications dans "Inhibition nerveuse" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Ave, Cleveland, Ohio, 44106.
Department of Biology, Case Western Reserve University, 2080 Adelbert Rd, Cleveland, Ohio, 44106.
Department of Neurosciences, Case Western Reserve University, 2210 Circle Drive, Cleveland, Ohio, 44106.
Publications dans "Inhibition nerveuse" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedical Engineering, Vanderbilt University, 5824 Stevenson Center, Nashville, Tennessee, 37232.
Biophotonics Center, Vanderbilt University, 410 24th Ave S, Nashville, Tennessee, 37232.
Department of Neurological Surgery, Vanderbilt University, 1161 21st Ave South, Nashville, Tennessee, 37232.
Publications dans "Inhibition nerveuse" :
2 publications dans cette catégorie
Affiliations :
Program in Brain, Behavior & Cognition, Department of Psychological and Brain Sciences, Boston University, Boston, MA, United States.
Publications dans "Inhibition nerveuse" :
2 publications dans cette catégorie
Affiliations :
Human Systems Neuroscience Laboratory, Department of Health Sciences, Boston University, Boston, MA, United States.
Department of Anatomy & Neurobiology, Boston University School of Medicine, Boston, MA, United States.
Center for Systems Neuroscience, Boston University, Boston, MA, United States.
Graduate Program for Neuroscience, Boston University, Boston, MA, United States.
Publications dans "Inhibition nerveuse" :
2 publications dans cette catégorie
Affiliations :
Center for Systems Neuroscience, Boston University, Boston, MA, United States.
Graduate Program for Neuroscience, Boston University, Boston, MA, United States.
Computational Neuroscience and Vision Laboratory, Department of Psychological and Brain Sciences, Boston University, Boston, MA, United States.
Publications dans "Inhibition nerveuse" :
2 publications dans cette catégorie
Affiliations :
Department of Psychology, University of Amsterdam, Amsterdam, Netherlands.
Amsterdam Brain and Cognition, University of Amsterdam, Amsterdam, Netherlands.
Department of Experimental and Applied Psychology, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Institute of Brain and Behaviour Amsterdam, Amsterdam, Netherlands.
Publications dans "Inhibition nerveuse" :
2 publications dans cette catégorie
Affiliations :
Department of Psychology, University of Amsterdam, Amsterdam, Netherlands.
Amsterdam Brain and Cognition, University of Amsterdam, Amsterdam, Netherlands.
Department of Experimental and Applied Psychology, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Institute of Brain and Behaviour Amsterdam, Amsterdam, Netherlands.
Publications dans "Inhibition nerveuse" :
2 publications dans cette catégorie
Affiliations :
Section on Development and Affective Neuroscience (SDAN), Emotion and Development Branch, National Institute of Mental Health.
Publications dans "Inhibition nerveuse" :
1 publication dans cette catégorie
Affiliations :
Lund University Cognitive Science, Lund University, Box 117, 221 00, Lund, Sweden.
Publications dans "Inhibition nerveuse" :
1 publication dans cette catégorie
Affiliations :
Lund University Cognitive Science, Lund University, Box 117, 221 00, Lund, Sweden. christian.balkenius@lucs.lu.se.
Publications dans "Inhibition nerveuse" :
1 publication dans cette catégorie
Affiliations :
Institute of Psychiatry and Neuroscience of Paris, INSERM U894, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Institut de Psychiatrie, CNRS, GDR3557, Paris, France. Electronic address: loic.carment@inserm.fr.
Publications dans "Inhibition nerveuse" :
1 publication dans cette catégorie
Affiliations :
Institute of Psychiatry and Neuroscience of Paris, INSERM U894, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Institut de Psychiatrie, CNRS, GDR3557, Paris, France.
Publications dans "Inhibition nerveuse" :
Acute migraine attacks disrupt performance and reduce the quality of life. Therefore, efforts to prevent these attacks continue using different medications. This study aimed to compare the effect of c...
This study aims to evaluate the effects of bevacizumab and propranolol from the point of view of a possible antiangiogenic effect in a model of primary nasal polyp (NP) tissue culture....
NP samples of 21 patients and normal healthy nasal mucosa samples of 7 patients were cultured. Samples were divided into four groups as follows (healthy nasal mucosa, NP without any treatment, NP trea...
Both propranolol and bevacizumab significantly decreased the expressions of VEGF-A and Ang-1, and they significantly increased the expression of Ang-2 in comparison to the control NP group. In the hea...
Bevacizumab and propranolol exert an antiangiogenic effect on NP tissues, mainly by decreasing VEGF-A and Ang-1 expression, increasing Ang-2 expression....
Treating infantile hemangiomas with oral propranolol may be initiated in accordance with various protocols some require hospitalization. However, different adverse events have been reported during tre...
The introduction of propranolol as systemic therapy for infantile hemangiomas (IH) has changed the natural history of these tumors. Cases presenting with ulceration, functional limitation, and viscera...
In the period 2011-2018 348 patients underwent systemic therapy with propanolol at a mean age of 3.5 months (range 1-10). The indications to begin the treatment were: visceral localization (10,6%), ul...
The minimum follow-up was 1 year. Propranolol was administered for a mean of 11 months (range: 6-19) and in 22 cases it was resumed for extra 4.5 months due to rebound. Overall, 97.4% responded to the...
The use of propranolol has considerably decreased the surgical indications for IH, improved the esthetic and functional outcome, and simplified the definitive surgical treatment. The response rate to ...
Propranolol, a nonselective beta-blocker used in the medical treatment of infantile Hemangioma (IH), has been shown to decrease the levels of vascular endothelial growth factor and reduce angiogenesis...
It has been reported that the storage, transport, and secretion of vascular endothelial growth factor (VEGF) are associated with platelet volume indices (PVI). We aimed to investigate the effect of pr...
While a statistically significant difference between months 0, 1, and 2 in PDW and MPV values was detected in the treated group, it was not detected in the untreated group. Taking into consideration t...
Consequently, in IH cases, propranolol response follow-up can be evaluated with PVIs, especially MPV and PDW, and it may facilitate clinicians' monitoring of the disease after propranolol administrati...
In this work, specific aptamers with affinity for S-propranolol were screened by SELEX technology based on the graphene oxide (GO) adsorption platform, and a GO-FAM labeled aptamer-propranolol fluores...
Propranolol is the first-line treatment for infantile hemangiomas (IH). Cases of propranolol-resistant infantile hemangiomas are rarely reported. The purpose of our study was to investigate the predic...
A prospective analytical study was conducted between January 2014 and January 2022 including all patients with IH who received oral propranolol therapy at a dose of 2-3 mg/kg/day maintained for at lea...
A total of 135 patients with IH were treated with oral propranolol. Poor response was reported in 18 (13.4%) of the patients: 72% were girls and 28% were boys. Overall, 84% of the IH were mixed, and h...
Poor response to propranolol therapy has rarely been reported in the literature. In our series, it was approximately 13.4%. To our knowledge, no previous publications have focused on the predictive fa...
Hyperthyroidism is a common endocrine disorder which leads to higher resting energy expenditure (REE). Increased activity of brown adipose tissue (BAT) contributes to elevated REE in hyperthyroid pati...
In the present prospective interventional trial we investigated the effect of propranolol on REE in hyperthyroid patients....
Nineteen patients with overt primary hyperthyroidism were recruited from the endocrine outpatient clinic. REE was measured by indirect calorimetry before and after an acute dose of 80mg propranolol an...
Mean REE decreased slightly after acute administration of 80mg propranolol (p= 0.03) from 1639 ± 307 kcal/24h to 1594 ± 283 kcal/24h. During the control visit REE did not change significantly. HR corr...
In hyperthyroid patients a single dose of propranolol reduced heart rate substantially but REE diminished only marginally probably due to reduced myocardial energy consumption. Our data speak against ...
ClinicalTrials.gov, identifier (NCT03379181)....
We aimed to evaluate the effects of thymoquinone and propranolol on Hep-2 cells representing laryngeal Ca cell type in comparison with cisplatin. We also evaluated their combined effects....
Apoptotic effects were directly analyzed via mitochondrial membrane potential and caspase-3 assays. In addition, effects on apoptosis and cell cycle via Bcl-2, Bax, P53, and Cyclin D1 mRNA expressions...
According to our results, it was determined that the anticancer effects of thymoquinone on Hep-2 cells were higher than propranolol. Our JC-1 and caspase-3 results showed an effect close to cisplatin,...
Thymoquinone induced apoptosis and blocked the cell cycle in Hep-2 cells. The effects of propranolol, which was reported to have an antiangiogenesis effect in some studies, on apoptosis and cell cycle...
Assess whether propranolol modulates the trigeminovascular system in both men and women....
We investigated the effect of propranolol (80 mg, 90 min after oral administration, corresponding to T...
Dermal blood flow responses to capsaicin were significantly attenuated after propranolol, but not after placebo. When stratifying by sex, no significant changes in the capsaicin-induced dermal blood f...
Propranolol (80 mg) inhibits capsaicin-induced increases in dermal blood flow in a sex-dependent manner. In patients, a more pronounced decrease in triptan use is observed in males when compared with ...